

CORRECTION

Open Access



Correction: Psychotropic and anti-epileptic drug use, before and after surgery, among patients with low-grade glioma: a nationwide matched cohort study

Isabelle Rydén^{1*}, Erik Thurin¹, Louise Carstam^{1,2}, Anja Smits¹, Sasha Gulati³, Roger Henriksson⁴, Øyvind Salvesen⁵ and Asgeir Store Jakola^{1,2,3}

Correction to: *BMC Cancer* 21, 248 (2021)

<https://doi.org/10.1186/s12885-021-07939-w>

Following publication of the original article [1], an error was discovered in table 3 “Logistic regression model for use of antidepressants, sedatives and anti-epileptics, respectively, at one year following index date, for patients with LGG.” In this table, the numbers presented for anti-epileptics are equal to the numbers for the sedatives. There has been a copy error and numbers need to be adjusted. The new results do not change the conclusions. The updated table 3 is given below and the changed values are displayed in bold typeface.

Author details

¹Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, University of Gothenburg, Sahlgrenska Academy, Blå stråket 7, 3 tr, 413 45 Gothenburg, Sweden. ²Department of Neurosurgery, Sahlgrenska University Hospital, Gothenburg, Sweden. ³Department of Neurosurgery, St. Olavs University Hospital HF, Trondheim, Norway. ⁴Department of Radiation Sciences and Oncology, University of Umeå, Umeå, Sweden. ⁵Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway.

Published online: 31 March 2022

Reference

1. Rydén I, Thurin E, Carstam L, et al. Psychotropic and anti-epileptic drug use, before and after surgery, among patients with low-grade glioma: a nationwide matched cohort study. *BMC Cancer*. 2021;21:248. <https://doi.org/10.1186/s12885-021-07939-w>.

The original article can be found online at <https://doi.org/10.1186/s12885-021-07939-w>.

*Correspondence: isabelle.ryden@neuro.gu.se

¹ Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, University of Gothenburg, Sahlgrenska Academy, Blå stråket 7, 3 tr, 413 45 Gothenburg, Sweden

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Covariate	Univariable		Multivariable	
	OR (95 % CI)	p-value	OR (95 % CI)	p-value
ANTIDEPRESSANTS				
Index year (per year)	1.22 (1.07-1.39)	0.002**	1.31 (1.11-1.55)	0.002**
Female (vs. male)	2.99 (1.60-5.60)	0.001**	3.41 (1.71-6.80)	0.001**
Age (per year)	1.02 (1.00-1.05)	0.027*	1.02 (1.00-1.05)	0.11
Income (per 100.000 SEK)	0.96 (0.76-1.20)	0.69	1.07 (0.83-1.39)	0.60
Higher education (vs. lower education)	0.94 (0.78-1.15)	0.56	0.97 (0.78-1.21)	0.78
History of depression	7.61 (3.88-14.94)	<0.001***	6.12 (2.96-12.63)	<0.001***
Use of antidepressants preoperatively	14.15 (5.88-34.08),	<0.001***		
Elixhauser comorbidity index (0, 1, 2, ≥3)	1.33 (0.96-1.84)	0.09	1.09 (0.75-1.59)	0.65
Functional level (per WHO performance status category)	0.98 (0.92-1.03)	0.38	0.96 (0.88-1.06)	0.42
Tumour size (6)	1.08 (0.96-1.21)	0.22	0.92 (0.79-1.07)	0.30
SEDATIVES				
Index year (per year)	1.13 (0.99-1.29)	0.07	1.12 (0.97-1.30)	0.14
Female (vs. male)	1.23 (0.66-2.30)	0.51	1.13 (0.58-2.19)	0.73
Age (per year)	1.02 (1.00-1.04)	0.09	1.02 (0.99-1.04)	0.24
Income (per 100.000 SEK)	0.87 (0.67-1.13)	0.30	0.90 (0.62-1.22)	0.49
Higher education (vs. lower education)	0.81 (0.66-1.00)	0.05	0.90 (0.71-1.13)	0.35
History of anxiety and/or sleeping difficulties	2.58 (1.36-4.90)	0.004**	2.14 (1.09-4.20)	0.027*
use of sedatives preoperatively	3.05 (1.60-5.82),	<0.001***		
Elixhauser comorbidity index (0, 1, 2, ≥3)	1.37 (0.98-1.92)	0.07	1.17 (0.80-1.70)	0.41
Functional level (per WHO performance status category)	0.97 (0.91-1.04)	0.42	0.97 (0.89-1.05)	0.43
Tumour size (6)	1.09 (0.97-1.23)	0.17	1.00 (0.87-1.16)	0.98
ANTI-EPILEPTICS				
Index year (per year)	1.00 (0.92-1.08)	1.00	1.01 (0.92-1.12)	0.83
Female (vs. male)	1.11 (0.75-1.64)	0.60	1.13 (0.71-1.82)	0.60
Age (per year)	1.00 (0.98-1.01)	0.64	1.00 (0.98-1.02)	0.93
Income (per 100.000 SEK)	1.02 (0.88-1.18)	0.79	0.94 (0.79-1.12)	0.49
Higher education (vs. lower education)	1.04 (0.92-1.19)	0.53	1.04 (0.87-1.23)	0.69
History of AED-use and/or seizure/epilepsy preoperatively	12.16 (7.15-20.69)	<0.001***	12.98 (7.53-22.37)	<0.001***
Elixhauser comorbidity index (0, 1, 2, ≥3)	0.90 (0.69-1.17)	0.42	0.93 (0.67-1.28)	0.64
Functional level (per WHO performance status category)	1.00 (0.99-1.01)	0.85	1.00 (0.98-1.01)	0.85
Tumour size (6)	1.03 (0.94-1.12)	0.58	1.00 (0.90-1.13)	0.94
Biopsy vs resection	0.78 (0.49-1.25)	0.30	0.67 (0.38-1.19)	0.17

*p < 0.05, **p < 0.01, ***p < 0.001